Lowe Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

Lowe Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-82	Closed	-$2K	–	307
2019 Q1	$2K	Buy	82 +45	+122%	+$1.37K	﹤0.01%	228
2018 Q4	$1K	Hold	37	–	–	﹤0.01%	235
2018 Q3	$2K	Hold	37	–	–	﹤0.01%	257
2018 Q2	$1K	Hold	37	–	–	﹤0.01%	225
2018 Q1	$1K	Hold	37	–	–	﹤0.01%	230
2017 Q4	$1K	Buy	+37	New	+$1.25K	﹤0.01%	237

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lowe Wealth Advisors's MYGN Position: Q2 2019 in Review

Lowe Wealth Advisors sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 82 shares — an estimated $2K sold.

Lowe Wealth Advisors first reported a position in MYGN in Q4 2017 and held it in 6 quarters. The position peaked at $2K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Lowe Wealth Advisors reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Lowe Wealth Advisors sold 82 Myriad Genetics shares in Q2 2019, an estimated $2K.
Lowe Wealth Advisors first reported a position in Myriad Genetics in Q4 2017 and held it in 6 quarters.
Lowe Wealth Advisors's Myriad Genetics position peaked at $2K in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Lowe Wealth Advisors's 13F filing for Q2 2019, filed 10 Jul 2019.